Company profile
Ticker
GUTS
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Fractyl Laboratories Inc.
SEC CIK
Corporate docs
IRS number
273553477
GUTS stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
1 Apr 24
8-K
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
1 Apr 24
8-K
Regulation FD Disclosure
1 Apr 24
S-8
Registration of securities for employees
6 Feb 24
8-K
Amendments to Articles of Incorporation or Bylaws
6 Feb 24
424B4
Prospectus supplement with pricing info
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
CERT
Certification of approval for exchange listing
1 Feb 24
SEC STAFF
SEC staff action: Order
1 Feb 24
CORRESP
Correspondence with SEC
30 Jan 24
Latest ownership filings
4
Adrian Kimber
2 Apr 24
3
Adrian Kimber
2 Apr 24
SC 13G
General Catalyst GP V, LLC
16 Feb 24
SC 13G
CVF, LLC
14 Feb 24
4
Change in insider ownership
8 Feb 24
4
Change in insider ownership
8 Feb 24
4
Change in insider ownership
8 Feb 24
4
Change in insider ownership
8 Feb 24
4
CLIVE MEANWELL
8 Feb 24
4
Ajay Royan
8 Feb 24
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Adrian Kimber | Stock Option Common Stock | Grant | Acquire A | No | No | 7.45 | 250,000 | 1.86 mm | 250,000 |
6 Feb 24 | CVF | Common Stock | Buy | Acquire P | No | No | 15 | 333,333 | 5.00 mm | 4,673,870 |
6 Feb 24 | CVF | Common Stock | Conversion | Acquire C | No | No | 0 | 920,661 | 0.00 | 4,340,537 |
6 Feb 24 | CVF | Common Stock | Conversion | Acquire C | No | No | 0 | 3,419,876 | 0.00 | 3,419,876 |
6 Feb 24 | CVF | Convertible Promissory Note Common Stock | Conversion | Dispose C | No | No | 0 | 0 | 0.00 | 0 |
6 Feb 24 | CVF | Series F Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 333,957 | 0.00 | 0 |
6 Feb 24 | CVF | Series E Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 2,914,228 | 0.00 | 0 |
6 Feb 24 | CVF | Series D Preferred Stock Common Stock | Conversion | Dispose C | No | No | 0 | 4,090,872 | 0.00 | 0 |
6 Feb 24 | Flynn James E | Common Stock | Conversion | Acquire C | Yes | No | 0 | 76,706 | 0.00 | 834,254 |
6 Feb 24 | Flynn James E | Common Stock | Conversion | Acquire C | Yes | No | 0 | 757,548 | 0.00 | 757,548 |
News
Why Cal-Maine Foods Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
3 Apr 24
Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
3 Apr 24
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
2 Apr 24
Fractyl Health On April 1 Reported Q4 Adj EPS $(8.02) Down From $(7.39) YoY, Sales $7.00K
2 Apr 24
PVH Posts Q4 Results, Joins Humana, CVS Health And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
2 Apr 24
Press releases
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
1 Apr 24
Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
12 Mar 24
Fractyl Health Announces Pricing of Initial Public Offering
1 Feb 24